CASR and breast cancer: Although the level of serum calcium in low grade BC patients may not be a prognostic indicator for survival, it is possible that the development of hypercalcemia in 10–30% of BC patients without evidence of skeletal metastases [49, 50] may at least in part be due to the expression of inactivating CaSR mutations especially at the rs1801725.